GlassScriptPhysician profile
Neha M Dunn
NPI 1154609030
$7,296.82
in general payments reported to CMS, 2019-2025
26 companies · $2,731 in 2025
The $2,731 reported for 2025 was more than what 77% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2021: $239 · 2022: $102 · 2023: $1,986 · 2024: $2,065 · 2025: $2,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,733 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,732.61 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,575.55 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $840.30 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $834.18 | 2023-2025 | Dupixent |
| Csl Behring | $798.83 | 2023-2025 | Haegarda, Hizentra, Andembry |
| Novartis Pharmaceuticals Corporation | $482.40 | 2023-2025 | |
| Genzyme Corporation | $480.10 | 2023-2025 | |
| Octapharma USA, INC. | $318.42 | 2023-2025 | Cutaquig |
| Takeda Pharmaceuticals U.S.A., INC. | $270.88 | 2023-2025 | Takhzyro, Cuvitru, Eohilia |
| Abbvie INC. | $255.78 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $254.19 | 2023-2025 | Orladeyo |
| Optinose US, INC. | $153.16 | 2023-2025 | |
| Pharming Healthcare, INC. | $144.06 | 2023-2025 | Ruconest |
| Pfizer INC. | $130.78 | 2023-2025 | |
| Ionis Pharmaceuticals, INC. | $125.06 | 2025 | Dawnzera |
| Grifols USA, LLC | $96.38 | 2023-2025 | Xembify, Prolastin-C Liquid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $93.34 | 2023-2025 | Tezspire |
| Kaleo, INC. | $85.49 | 2023-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $78.32 | 2025 | Neffy |
| Genentech USA, INC. | $60.43 | 2023-2024 | Xolair |
| Organon LLC | $58.35 | 2025 | Vtama |
| Mylan Specialty L.P. | $39.40 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $38.33 | 2023 | |
| Tersera Therapeutics LLC | $26.86 | 2023 | Quzyttir |
| Phadia US INC. | $24.97 | 2024 | Immunocap |
| Paratek Pharmaceuticals, INC. | $17.28 | 2025 | Xhance |
| Galderma Laboratories, L.P. | $13.98 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.